SCHEMBL17827430

SCHEMBL17827430

c1ccc(C2(c3ccc(-c4ccc(N(c5ccc6c(c5)oc5ccccc56)c5ccc6c(c5)oc5ccccc56)cc4)cc3)c3ccccc3-c3ccccc32)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
MAPT P10636 4/20 0.36
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 1/20 0.36
OPRK1 P41145 1/20 0.36
AHR P35869 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
MMP12 P39900 1/20 0.33
MMP13 P45452 1/20 0.33
ALOX5 P09917 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
TNKS O95271 1/20 0.32
TTR P02766 1/20 0.31
PLA2G2A P14555 1/20 0.31
PLA2G4A P47712 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17804833 0.96 MEN1 (0.39) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL17827438 0.96 PLA2G2A (0.35) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL22150231 0.96 MEN1 (0.33) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL17790269 0.94 PDK2 (0.34) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL24255765 0.94 AHR (0.33) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL18326161 0.94 MMP12 (0.37) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL18326168 0.94 MMP12 (0.37) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL22920806 0.94 KDM4E (0.32) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL18118722 0.94 MEN1 (0.32) MEN1KMT2AMAPTKDM4ESMN1; SMN2
SCHEMBL21239192 0.93 KDM4E (0.33) MEN1KMT2AMAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9929355-B2 Amine compound and organic electroluminescent device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-03-27 US disclosed
US-9929355-B2 Amine compound and organic electroluminescent device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-03-27 US disclosed
US-20160172593-A1 AMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2016-06-16 US disclosed
US-20160172593-A1 AMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160172593-A1 AMINE COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE INCLUDING THE SAME AOC2, SAT1, ODC1 MEN1 507/4885KMT2A 313/4885MAPT 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.